BioNxt Solutions Announces Debenture Unit Financing
BioNxt Solutions has announced a non-brokered private placement of debenture units to raise up to $2.5 million. Each debenture unit consists of $0.50 in principal amount, bearing an 8% annual interest rate for two years, and is convertible into common shares. The units also include one Common Share purchase warrant exercisable at $0.60 for two years.
The company may pay interest through common shares at $0.50 per share. Additionally, BioNxt plans to issue up to 400,000 compensation warrants at $0.50 per warrant to eligible finders, along with up to 8% finder's fee in cash. All securities will have a four-month and one-day hold period from issuance. The offering's completion is subject to regulatory approvals.
BioNxt Solutions ha annunciato un collocamento privato di unità di obbligazioni senza intermediari per raccogliere fino a 2,5 milioni di dollari. Ogni unità di obbligazione consiste in un importo principale di $0,50, con un tasso di interesse annuale dell'8% per due anni, ed è convertibile in azioni ordinarie. Le unità includono anche un warrant per l'acquisto di azioni ordinarie esercitabile a $0,60 per due anni.
La società può pagare gli interessi attraverso azioni ordinarie a $0,50 per azione. Inoltre, BioNxt prevede di emettere fino a 400.000 warrant di compensazione a $0,50 per warrant per i cercatori idonei, insieme a una commissione per il cercatore fino all'8% in contanti. Tutti i titoli avranno un periodo di blocco di quattro mesi e un giorno dall'emissione. Il completamento dell'offerta è soggetto ad approvazioni regolatorie.
BioNxt Solutions ha anunciado una colocación privada de unidades de debentures sin intermediarios para recaudar hasta $2.5 millones. Cada unidad de debenture consiste en un monto principal de $0.50, con una tasa de interés anual del 8% durante dos años, y es convertible en acciones comunes. Las unidades también incluyen un warrant de compra de acciones comunes que se puede ejercer a $0.60 durante dos años.
La empresa puede pagar intereses a través de acciones comunes a $0.50 por acción. Además, BioNxt planea emitir hasta 400,000 warrants de compensación a $0.50 por warrant para buscadores elegibles, junto con una tarifa de búsqueda de hasta el 8% en efectivo. Todos los valores tendrán un período de retención de cuatro meses y un día a partir de la emisión. La finalización de la oferta está sujeta a aprobaciones regulatorias.
BioNxt Solutions는 중개인 없이 채권 단위를 사모 배정하여 최대 250만 달러를 모금할 것이라고 발표했습니다. 각 채권 단위는 $0.50의 원금으로 구성되어 있으며, 연 8%의 이자율이 2년 동안 적용되며, 보통주로 전환 가능합니다. 이 단위에는 또한 2년 동안 $0.60에 행사할 수 있는 보통주 구매 워런트가 포함되어 있습니다.
회사는 주당 $0.50로 보통주를 통해 이자를 지급할 수 있습니다. 또한 BioNxt는 자격이 있는 중개인에게 $0.50의 워런트로 최대 400,000개의 보상 워런트를 발행할 계획이며, 현금으로 최대 8%의 중개 수수료를 지급할 예정입니다. 모든 증권은 발행일로부터 4개월 1일의 보유 기간이 있습니다. 제안의 완공은 규제 승인에 따라 달라집니다.
BioNxt Solutions a annoncé un placement privé sans intermédiaire d'unités d'obligations pour lever jusqu'à 2,5 millions de dollars. Chaque unité d'obligation se compose d'un montant principal de 0,50 $, portant un taux d'intérêt annuel de 8% pendant deux ans, et est convertible en actions ordinaires. Les unités incluent également un bon de souscription d'actions ordinaires pouvant être exercé à 0,60 $ pendant deux ans.
La société peut payer des intérêts par le biais d'actions ordinaires à 0,50 $ par action. De plus, BioNxt prévoit d'émettre jusqu'à 400 000 bons de compensation à 0,50 $ par bon pour les intermédiaires éligibles, ainsi qu'une commission de recherche pouvant atteindre 8 % en espèces. Tous les titres auront une période de blocage de quatre mois et un jour à compter de l'émission. L'achèvement de l'offre est soumis à des approbations réglementaires.
BioNxt Solutions hat eine nicht vermittelte Privatplatzierung von Anleiheneinheiten angekündigt, um bis zu 2,5 Millionen Dollar zu sammeln. Jede Anleiheneinheit besteht aus einem Nennbetrag von 0,50 $, der einen jährlichen Zinssatz von 8% für zwei Jahre trägt und in Stammaktien umwandelbar ist. Die Einheiten beinhalten auch einen Kaufwarrant für Stammaktien, der für zwei Jahre zu 0,60 $ ausgeübt werden kann.
Das Unternehmen kann Zinsen in Form von Stammaktien zu 0,50 $ pro Aktie zahlen. Darüber hinaus plant BioNxt, bis zu 400.000 Vergütungswarrants zu 0,50 $ pro Warrant an berechtigte Vermittler auszugeben, sowie eine Vermittlungsgebühr von bis zu 8 % in bar. Alle Wertpapiere unterliegen einer Haltedauer von vier Monaten und einem Tag ab der Emission. Der Abschluss des Angebots unterliegt behördlichen Genehmigungen.
- Raising up to $2.5 million in new capital
- 8% interest rate offering attractive terms for investors
- Flexible payment structure allowing interest payment through share issuance
- Potential dilution of existing shareholders through conversion of debentures and warrants
- Additional dilution from finder's warrants and fees
- High 8% interest rate indicates expensive financing terms
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), announces a non-brokered private placement of debenture units (the "Debenture Units") with each unit consisting of
The Company anticipates issuing up to 400,000 compensation warrants (the "Finders Warrants") exercisable into one common share in the capital of the Company each at
All securities issued in connection with the Offering, including the Finders Warrants, will be subject to a hold period of four months and one day from the date of issuance. Completion of the Offering is subject to a number of conditions, including but not limited to, receipt of any regulatory approvals as necessary.
This news release does not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Debentures, Warrants, and the underlying Common Shares which may be issued on exercise of each, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 604-250-6162
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
What is the size of BioNxt Solutions' (BNXTF) February 2025 debenture offering?
What are the key terms of BNXTF's February 2025 debenture units?
How many finder's warrants will BNXTF issue for the February 2025 offering?
What is the hold period for BNXTF's February 2025 debenture securities?
